Product Description
an oral, non-systemic approach to weight loss
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gelesis
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT04257123 | N/A |
Completed |
Overweight|Obesity|Weight Loss |
2020-11-30 |
|
GLOW-EX | N/A |
Completed |
Obesity|Overweight |
2017-12-08 |
|
G-04 | N/A |
Completed |
Obesity|Overweight |
2017-06-01 |
|
GS-100-006 | N/A |
Completed |
Obesity|Overweight |
2016-07-01 |